TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Exenatide Plus Metformin vs. Insulin Aspart Plus Metformin on Glycemic Control and Hypoglycemia in Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have been treated with diet and exercise and a stable, maximally tolerated dose of immediate-release or extended-release metformin, or the combination of metformin (any dosage) with sulfonylurea/meglitinides for at least 3 months prior to study start~* Have not received thiazolidinediones, or alpha-glucosidase inhibitors for longer than 2 weeks within 3 months prior to study start, and have not received any insulin formulation for more than 14 days (other than in emergency situations) and within 14 days prior to study start~* Have an HbA1c between 6.5% and 10.0%, inclusive~* Have a body mass index (BMI) between 25 kg/m\^2 and 40 kg/m\^2, inclusive~Exclusion Criteria:~* Have type 1 diabetes or known latent autoimmune diabetes in adults~* Are receiving chronic (lasting longer than 2 weeks) systemic glucocorticoid therapy (excluding topical and inhaled preparations) or have received such therapy within 2 weeks prior to study start~* Are receiving treatment for gastrointestinal disease with a drug directly affecting gastrointestinal motility (e.g., metoclopramide, cisapride, and chronic macrolide antibiotics)~* Have used any prescription drug to promote weight loss within 3 months prior to study start~* Have received treatment within 30 days prior to study start with a drug that has not received regulatory approval for any indication at the time of study entry~* Have previously completed or withdrawn from this study or any other study investigating exenatide or GLP-1 analogs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Exenatide Twice Daily (BID) (Type: EXPERIMENTAL): None
- Premixed Insulin Aspart Twice Daily (BID) (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: IL-11 in Women With Von Willebrand Disease and Refractory Menorrhagia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Females 18-45 years of age~* Confirmed type 1 VWD, as defined by low VWF:RCoF or low VWF:Ag and qualitatively normal VWF multimers~* Menorrhagia refractory to estrogens, hormones, hemostatic agents~* Willingness to have blood drawn~Exclusion Criteria:~* Use of immunomodulatory or experimental drugs, or diuretics~* Pregnant or lactating women or those unwilling to use contraception during study~* Previous cardiac disease, congestive failure, arrhythmia (e.g., atrial fibrillation, atrial flutter), hypertension, MI, stroke, or thrombosis~* Past allergic reaction to Neumega or DDAVP~* Surgery within the past 8 weeks~* Inability to comply with study protocol requirements~* Concomitant use of antiplatelet drugs, anticoagulants, dextran, aspirin or NSAIDs~* Treatment with DDAVP, cryoprecipitate, whole blood, plasma and plasma derivatives containing substantial quantities of FVIII and/or VWF within five days of study

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Oprelvekin, Interleukin 11, IL-11 (Type: EXPERIMENTAL): 25 micrograms/kg by subcutaneous injection once daily for four days, then once daily on day 1-7 during each of six consecutive menstrual cycles

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: LAS41005 in Hyperkeratotic Actinic Keratosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Main Inclusion Criteria:~* Signed and dated written informed consent.~* Men and women aged between 18 and 85 years inclusive.~* Have a general good and stable health condition as confirmed by a physical examination and by medical history.~* Have at least 4 but not more than 10 clinically confirmed hyperkeratotic AK target lesions of moderate to severe intensity within the face/forehead or bald scalp~* Skin type I to IV according to Fitzpatrick's .~* Are free of any significant physical abnormalities (e.g., tattoos, dermatoses) in the potential treatment area that may cause difficulty with examination or final evaluation.~* Physical ability to apply the study preparation correctly and to follow the study restrictions and visit.~* Women of childbearing potential are allowed to participate in this study, only if they use a highly effective method of contraception~Main Exclusion Criteria:~* Have received treatment of AK within the treatment area (face / scalp) in the three months preceding this clinical trial.~* Have known hypersensitivity to the ingredients~* Are subjects under immunosuppressive therapy.~* Having coagulation defects which are inherited or acquired~* Have evidence of clinically significant, unstable medical conditions~* Have currently other malignant or benign tumors of the skin within the treatment area~* Subjects who have taken topical or systemic treatments that might interfere with the study end points, within a time window that is not allowed, or who are currently taking phenytoin, methotrexate or sulfonylurea.~* Subjects taking inhibitors of DPD (e.g. Brivudin, Sorivudin)~* Are known to be pregnant or lactating (currently or within the past 3 months).~* Have any dermatological disease in the treatment area or surrounding area that may be exacerbated by treatment~* Are currently or within the past 8 weeks participating in another clinical study.~* Have active chemical dependency or alcoholism as assessed by the investigator.~* Subject is institutionalized because of legal or regulatory order.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Drug Las41005
- 2 (Type: OTHER): Cryotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Teriparatide or Zoledronic Acid Treatment on Bone in Postmenopausal Osteoporotic Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ambulatory, postmenopausal women with osteoporosis (no vaginal bleeding for at least 2 years prior to trial entry)~* Free of severe or chronically disabling conditions other than osteoporosis that will impair ability to complete the trial~* Bone mineral density (BMD) T-score of at least -2.5 at the femoral neck, total hip, or lumbar spine (L1-L4, with at least 2 evaluable vertebrae), with or without atraumatic fracture or,~* Bone mineral density (BMD) T-score of at least -1.5 at the femoral neck, or total hip, or lumbar spine (L1-L4, with at least 2 evaluable vertebrae), and either 1 or more atraumatic vertebral fracture(s) or an atraumatic nonvertebral fracture in the opinion of the investigator. Nonvertebral fracture sites allowed are wrist, hip, pelvis, ribs, humerus, clavicle, leg (femur, tibia, and fibula, excluding the ankle).~* Serum calcium, parathyroid hormone (PTH), alkaline phosphatase must be within normal reference range~Exclusion Criteria:~* Have an increased risk of osteosarcoma (bone tumor); this includes Paget's disease of bone, a previous bone tumor, or radiation involving the skeleton~* Are allergic or cannot tolerate teriparatide or zoledronic acid or any of their ingredients or components~* Are allergic to tetracycline~* Have a history of exposure to tetracycline therapy in the 3 months prior to trial entry~* Have participated in a prior PTH clinical trial or received prior treatment with teriparatide, PTH, or other related medications~* Have a vitamin D level below 10 nanogram/milliliter (ng/mL)~* Have a condition that could possibly put one at risk for an adverse event due to the bone biopsy procedure (e.g. bleeding disorder)~* Have undergone two previous iliac crest bone biopsies (one in each iliac crest)~* Have taken any intravenous (IV) osteoporosis medication~* Have taken other oral osteoporosis medications and have not been off of them for a specific period of time before trial entry~* Have a history of certain cancers in the 5 years prior to trial entry~* Have active liver disease~* Have significantly impaired kidney function~* Currently have active or suspected diseases that affect the bones, other than osteoporosis~* Have active or recent history of significant gastrointestinal (stomach or intestinal) disorders~* Have been treated with certain glucocorticoids for more than 30 days in the past 1 year prior to trial entry

- Gender: FEMALE
- Minimum Age: 55 Years
- Maximum Age: 89 Years
- Healthy Volunteers: f

Study Arms:
- Teriparatide (Type: EXPERIMENTAL): None
- Zoledronic Acid (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Psilocybin for the Treatment of Migraine Headache

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of migraine headache per ICHD-3beta criteria~* Typical pattern of migraine attacks with approximately two migraines or more weekly~* Attacks are managed by means involving no more than twice weekly triptan use~* Age 21 to 65~Exclusion Criteria:~* Axis I psychotic disorder (e.g. schizophrenia, bipolar I, depression with psychosis)~* Axis I psychotic disorder in first degree relative~* Unstable medical condition, severe renal, cardiac or hepatic disease, pacemaker, or serious central nervous system pathology~* Pregnant, breastfeeding, lack of adequate birth control~* History of intolerance to psilocybin, LSD, or related compounds~* Drug or alcohol abuse within the past 3 months (excluding tobacco)~* Urine toxicology positive to drugs of abuse~* Use of vasoconstrictive medications (i.e. sumatriptan, pseudoephedrine, midodrine) within 5 half-lives of test days~* Use of serotonergic antiemetics (i.e. ondansetron) in the past 2 weeks~* Use of antidepressant medication (i.e. TCA, MAOI, SSRI) in the past 6 weeks~* Use of steroids or certain other immunomodulatory agents (i.e. azathioprine) in the past 2 weeks

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo/Low Dose Psilocybin (Type: EXPERIMENTAL): Subjects in this arm receive placebo in the first session and low dose psilocybin in the second session.
- Placebo/High Dose Psilocybin (Type: EXPERIMENTAL): Subjects in this arm receive placebo in the first session and high dose psilocybin in the second session.
- Low Dose Psilocybin/Placebo (Type: EXPERIMENTAL): Subjects in this arm receive low dose psilocybin in the first session and placebo in the second session.
- High Dose Psilocybin/Placebo (Type: EXPERIMENTAL): Subjects in this arm receive high dose psilocybin in the first session and placebo in the second session.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Compare Efficacy and Safety of Mycamine® and Itraconazole for Preventing Fungal Infections

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients at risk of systemic fungal infections due to their immunocompromised state due to one of the following:~  * Patient with a hematologic malignancy undergoing an autologous hematopoietic stem cell transplant~ * Any patient undergoing an allogeneic hematopoietic stem cell transplant~Exclusion Criteria:~* Patients with moderate or severe liver disease, as defined by:~  * AST or ALT greater than 5 times upper limit of normal (ULN), OR;~ * Total bilirubin greater than 2.5 times ULN~* Patients with evidence of a deeply invasive or disseminated fungal infection at time of enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 1. Micafungin (Type: EXPERIMENTAL): None
- 2. Itraconazole (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Stryker Triathlon Total Knee System for Total Knee Arthroplasty Implanted Using ShapeMatch® Cutting Guides: Sub-Study B

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* The patient is a male or non-pregnant female between the ages of 50-90.~* The patient requires a primary total knee replacement and is indicated for computer-assisted surgery.~* The patient has a primary diagnosis of osteoarthritis (OA).~* The patient has intact collateral ligaments.~* The patient is able to undergo MRI scanning of the affected limb.~* The patient has signed the study specific, HREC-approved, Informed Consent document.~* The patient is willing and able to comply with the specified pre-operative and post-operative clinical and radiographic evaluations.~Exclusion Criteria:~* The patient has a history of total, unicompartmental reconstruction or fusion of the affected joint.~* The patient has had a high tibial osteotomy or femoral osteotomy.~* The patient is morbidly obese (BMI ≥ 40).~* The patient has a deformity which will require the use of stems, wedges or augments in conjunction with the Triathlon Total Knee System.~* The patient has a varus/valgus malalignment ≥ 15° (relative to mechanical axis).~* The patient has a fixed flexion deformity ≥ 15°.~* The patient has a neuromuscular or neurosensory deficiency, which would limit the ability to assess the performance of the device.~* The patient has a systemic or metabolic disorder leading to progressive bone deterioration.~* The patient is immunologically suppressed or receiving steroids in excess of normal physiological requirements.~* The patient has a cognitive impairment, an intellectual disability or a mental illness.~* The patient is pregnant.~* The patient has metal hardware present in the region of the hip, knee or ankle (as this is known to create geometrical distortion in the region of the implant).~* The patient has any known contraindications for undergoing assessment by MRI (e.g. ferrous implants, metallic clips, magnetically activated implanted devices such as cardiac pacemakers, etc).

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- ShapeMatch Cutting Guides with Triathlon (Type: OTHER): The ShapeMatch® Cutting Guides are intended to be used as patient-specific surgical instrumentation to assist in the positioning of knee arthroplasty components intra-operatively and in guiding the marking of bone before cutting.~They are intended for single use only.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of GLPG0634 in Subjects With Active Crohn's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects between 18 and 75 years~* Documented history of ileal, colonic, or ileocolonic CD~* CDAI score ≥ 220 to ≤ 450~* Evidence of active inflammation as demonstrated by endoscopic confirmation of active disease~* Subjects previously not exposed to anti-TNF treatment (TNF-naïve) or subjects previously exposed to anti-TNF therapy at a registered dose, that has been discontinued at least 8 weeks prior to Screening and deemed by the treating physician as a primary or secondary non-responder or intolerant (TNF-experienced)~* Continuation of concurrent treatment with oral steroids (≤30 mg prednisolone eq/day), mesalazine, olsalazine, CD-related antibiotics and probiotics at stable dose is allowed~* Previous exposure to immunomodulators is permitted, but must be discontinued~* Haematology and biochemistry lab parameters within predefined ranges as stated in the protocol~Exclusion Criteria:~* Diagnosis of indeterminate colitis, ulcerative colitis (UC), or clinical findings suggestive of UC~* Stoma, gastric or ileoanal pouch, procto- or total colectomy, symptomatic stenosis or obstructive strictures, history of bowel perforation, (suspected) abscess; actively draining fistulae~* Subject who has had surgical bowel resections within the past 6 months, short bowel syndrome or is receiving tube feeding, defined formula diets, or parenteral alimentation~* Subject with positive Clostridium difficile toxin stool assay or evidence of any other gastrointestinal infection~* Subject who has received non-permitted IBD therapies within specified timeframes, depending on the medication, as stated in the protocol~* Subject with a (previous history of) dysplasia of the gastrointestinal tract~* Concurrent gastro-intestinal malignancy or a history of cancer elsewhere~* History of lymphoproliferative disease~* Known active infection of any kind, current therapy for chronic infection or history of specific infections as stated in the protocol~* Subject who is pregnant, lactating or not willing to maintain highly effective birth control methods during the course of the study and 12 weeks thereafter

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- GLPG0634 200 mg QD (Type: EXPERIMENTAL): 2 tablets of 100 mg GLPG0634 in the morning
- GLPG0634 100 mg QD (Type: EXPERIMENTAL): 1 tablet of 100 mg GLPG0634 and 1 placebo tablet in the morning
- Placebo QD (Type: PLACEBO_COMPARATOR): 2 placebo tablets in the morning

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Epileptic Seizures in Acute intraCerebral Haemorrhage

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age greater than 18 years with no upper age limit~* Competent adult patient.~* Patient affiliated to the French National Health Insurance.~* Patient with supratentorial spontaneous intracerebral hemorrhage diagnosed by CT or MRI~* Early neurological symptoms less than 24 hours~* NIHSS score on admission between 5 and 25~* Informed consent given by the patient or his legal representative~Exclusion Criteria:~* Inaugural Seizures ( at the onset of symptoms associated with intracerebral hemorrhage )~* Seizures occurring between the inclusion of the patient and the start of the EEG~* Other Intracerebral hemorrhage infratentorial , post-traumatic , related to a vascular malformation or an underlying tumor and secondarily hemorrhagic cerebral infarction~* Current antiepileptic treatment when intracerebral hemorrhage , or a history of epilepsy~* Modified Rankin Scale before intracerebral hemorrhage \> 1 (indicating a preexisting disability)~* Serious illness which can affect the prognosis within 3 months~* Severe renal impairment ( creatinine clearance \<30 ml / min)~* Pregnancy, lactation~* Known hypersensitivity to levetiracetam or other pyrrolidone derivatives , or any of the excipients.~* Untreated severe depression , psychotic disorders~* Lactose Intolerance~* Patient under measuring socio- legal protection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lévétiracetam (Type: EXPERIMENTAL): 52 patients will be recruited over 2 years in the experimental group
- Placebo (Type: PLACEBO_COMPARATOR): 52 patients will be recruited over 2 years in the control group

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Measuring Outcomes In Patients With Pulmonary Arterial Hypertension Not on Active Treatment (MOTION)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients, 18 to 80 years of age at Visit 0~* Women of childbearing potential must have a negative pre-treatment pregnancy test, negative monthly pregnancy test, and must use reliable methods of contraception according to the Risk Evaluation Mitigation Strategies (REMS) guidance~* Symptomatic pulmonary arterial hypertension, World Health Organization Group 1 with a pulmonary vascular resistance (PVR) \>300 dyn\*sec\*cm-5, mean pulmonary artery pressure (PAP mean) ≥25 mmHg, and pulmonary capillary wedge pressure (PCWP) ≤15 mmHg as assessed by right heart catheterization within 6 months prior to Screening (Visit 0)~* PAH of the following types:~Idiopathic (IPAH) Familial (FPAH)~Associated with PAH (APAH) due to:~Connective tissue disease Congenital heart disease, but only if patient underwent surgical repair more than one year before enrollment Anorexigen or amphetamine use Portal hypertension with liver cirrhosis~* Not treated with PAH-specific pulmonary medications within 14 days of Screening (Visit 0)~* 6MWD between 150 meters and 450 meters~Exclusion Criteria:~* Patients who are pregnant~* Patients currently on nitrate and/or nitric oxide (NO) donor therapy; patients currently taking phosphodiesterase 5 (PDE5) inhibitors (such as sildenafil, tadalafil, vardenafil) and non-specific PDE inhibitors (theophylline, dipyridamole)~* Non-WHO group 1 Pulmonary Hypertension~* Severe restrictive lung disease~* History of uncontrolled high blood pressure or hypotension~* A medical disorder, condition, or history that in the opinion of the Investigator would impair their ability to participate or complete this study~* Active state of hemoptysis or pulmonary hemorrhage, including those events managed by bronchial artery embolization

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Riociguat 0.5mg to 2.5 mg (Type: EXPERIMENTAL): Single arm, open label

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete